Axon's potential to compound for a long time makes it look undervalued. x.com 

Axon is attempting to start a new Stage 2 uptrend in Stan Weinstein's Stage Analysis, the transition that often produces the biggest winners. It completed a Stage 4 decline, built a six-month Stage 1 base, and reclaimed its 200-day moving average and all-time-high anchored VWAP. The public-safety ecosystem of TASERs, body cameras and AI software is projected to grow revenue from $3.0B to $6.1B by 2028 and EPS from $2.98 to $13.73. x.com 

Axon Enterprise looks weak in the near term: it has given up most of its post-earnings gains and more, and a massive rejection at the 100-day moving average created significant risk for those who chased the earnings pop. It may look like a great opportunity, but there is still too much macro uncertainty. That came despite strong results, with revenue up 39% and 122% net revenue retention; an unexpected positive announcement could still lift the stock. x.com  x.com 

AXT looks good on the dip because its blowout quarter has de-risked the stock. x.com 

Axon is a buy because Trump is buying it. x.com 

Axon still trades at about 50x forward earnings despite falling roughly 50% from its all-time high, a reminder to avoid overpaying for growth. x.com 

Axon's very strong Q1 and rising bookings support its growth case. Revenue was $807 million versus $779 million expected, EPS $1.61 versus $1.60, and net retention 125%. It guides 2026 revenue growth of 30-32%, with future contracted bookings up 44%. Stock-based compensation remains the main drawback, with about 4.5% share dilution that is high but should come down materially over time. x.com  x.com 

Axon delivered another elite quarter, reinforcing its standing as a compounding machine. x.com 

Axon still looks a little expensive even after falling 60% from its highs, and it only looks cheap at a forward P/E in the 20s, around the $250s. Revenue is expected to grow 30% a year for two to three years and its forward sales multiple has compressed from 22.9 to 7.8 times. Support should hold in the high $320s; a tiny swing position is justified only above $325. x.com 

AXT's new public offering should push the stock down. x.com